Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 395, 431 (1 October 1998) | doi:10.1038/26602
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Senior Scientist, Cellular & Molecular Pharmacology
- Cortex Search Inc.
- Vancouver, British Columbia
University Full-Professor (W3, Tenure Track)
- University of Münster
- Munster 48149 Germany
Hope or hype for lexipafant?
Fikri M. Abu-Zidan1
- Department of Surgery, Auckland Hospital, Faculty of Medicine and Health Science, University of Auckland, Park Road, Auckland, New Zealand
e-mail: Email: f.abu-zidan@auckland.ac.nz
I read the News article on the large multicentre trial of lexipafant (Zacutex) in severe pancreatitis and the response of the chief executive of British Biotechnology (Nature 393, 291; 1998, Nature 393, 299; 1998 & Nature 393, 509; 1998). I used lexipafant to block platelet-activating factor in different models of shock and sepsis during 1993-95 at Linköping University, Sweden.
To read this story in full you will need to login or make a payment (see right).
